MediWound (NASDAQ:MDWD) Downgraded to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of MediWound (NASDAQ:MDWD) from a hold rating to a strong sell rating in a research report released on Saturday morning.

MDWD has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $36.00 target price (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Finally, Zacks Research upgraded MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $31.67.

MediWound Stock Performance

Shares of MediWound stock opened at $17.03 on Friday. The firm has a 50-day moving average of $17.70 and a 200-day moving average of $17.87. MediWound has a 52-week low of $14.14 and a 52-week high of $22.50. The stock has a market cap of $218.15 million, a PE ratio of -8.11 and a beta of 0.13.

MediWound (NASDAQ:MDWD) last released its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. The business had revenue of $1.87 million for the quarter, compared to analyst estimates of $2.09 million. MediWound had a negative net margin of 140.80% and a negative return on equity of 70.55%. Equities research analysts predict that MediWound will post -2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

A number of large investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of MediWound in the 4th quarter valued at $26,000. BNP Paribas Financial Markets lifted its position in shares of MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 723 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new position in MediWound in the fourth quarter valued at about $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound News Summary

Here are the key news stories impacting MediWound this week:

• Positive Sentiment: 2026–2027 revenue guidance raised/outlined above street expectations — the company issued a 2026 revenue target of $24M–$26M (vs. consensus ~$22.6M) and 2027 guidance of $32M–$35M (vs. consensus ~$25.8M), suggesting material top‑line growth ahead if execution stays on track. MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs
• Positive Sentiment: Clinical and manufacturing progress: EscharEx Phase III (VALUE) is advancing as planned, NexoBrid manufacturing capacity has been expanded and is operational, and management expects regulatory approvals in 2026 — these operational milestones de‑risk near‑term commercialization upside. The company also finished the year with roughly $54M in cash. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Company filed its Form 20‑F for fiscal 2025 (routine disclosure). This is standard compliance and provides more detail for investors but is not a catalyst by itself. MediWound Files Annual Report on Form 20-F
• Neutral Sentiment: Earnings call transcript and details are available for investors who want management color on 2026 assumptions and the EscharEx program; use this to judge credibility of guidance and timing of approvals. MediWound (MDWD) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 revenue missed expectations — reported quarterly revenue of $1.87M vs. analysts’ ~$2.09M estimate, highlighting a small current revenue base and near‑term sensitivity to sales execution. MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Still unprofitable with wide negative margins — Q4 GAAP loss of $0.56/sh (a smaller loss than expected), but the company reported negative net margin and return on equity, underscoring continued cash burn risk until commercial scale or regulatory approvals materialize. That combination helps explain downward pressure on the stock today. MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.